pirfenidone has been researched along with Chronic Illness in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 12 (57.14) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Morrow, T | 1 |
| Glassberg, MK | 1 |
| Bargagli, E; Bennett, D; De Vita, E; Fossi, A; Lanzarone, N; Luzzi, L; Paladini, P; Perillo, F; Rottoli, P; Sestini, P | 1 |
| Chen, J; Guo, H; Huang, J; Peng, X; Wang, J | 1 |
| Leslie, K; Morell, F; Raghu, G; Vasakova, M; Walsh, S | 1 |
| Elia, D; Harari, S; Humbert, M | 1 |
| Blackwell, TS; Kropski, JA | 1 |
| Kishaba, T | 1 |
| He, JM; Qiu, ZZ; Yu, ZH; Zhang, HX; Zhang, ZW; Zhou, H | 1 |
| Almeda-Valdes, P; Escobar-Jiménez, JJ; Gómez-Pérez, FJ; Janka-Zires, M; Juárez-Comboni, SC; López-Gutiérrez, J; Uribe-Wiechers, AC | 1 |
| Rockey, DC | 1 |
| Chikanishi, T; Fujimori, A; Itoh, H; Iwatsuki, Y; Nakajima, H; Okada, M; Takakuta, K; Tanokura, A; Yamamoto, M | 1 |
| Cho, ME; Kopp, JB | 1 |
| Shah, SV | 1 |
| Kagouridis, K; Kolilekas, L; Manali, ED; Papiris, SA; Triantafillidou, C; Tsangaris, I | 1 |
| Hamada, K; Izumi, T; Nagai, S; Shigematsu, M; Taniyama, M; Yamauchi, S | 1 |
| Fernandez, F; Jendrisak, M; Margolin, SB; Marshbank, S; McKane, BW; Mohanakumar, T; Narayanan, K | 1 |
| Latham, CW; Margolin, SB; Visner, GA; Zander, DS; Zhou, H | 1 |
| Shihab, FS | 1 |
| Dosanjh, A | 1 |
| Fukagawa, M; Kurokawa, K; Noda, M; Shimizu, T | 1 |
7 review(s) available for pirfenidone and Chronic Illness
| Article | Year |
|---|---|
Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape.
Topics: Age Distribution; Aging; Antineoplastic Agents; Chronic Disease; Comorbidity; Disease Progression; Health Expenditures; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Patient Education as Topic; Practice Guidelines as Topic; Pyridones; Sex Distribution | 2019 |
Pulmonary Hypertension in Parenchymal Lung Diseases: Any Future for New Therapies?
Topics: Antihypertensive Agents; Chronic Disease; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endpoint Determination; Epoprostenol; Forecasting; Guanylate Cyclase; Humans; Hypertension, Pulmonary; Indoles; Lung Diseases, Interstitial; Phosphodiesterase 5 Inhibitors; Pilot Projects; Protein-Tyrosine Kinases; Pulmonary Disease, Chronic Obstructive; Pyridones | 2018 |
Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis.
Topics: Aged; Biopsy, Needle; Chronic Disease; Comprehension; Disease Management; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Immunohistochemistry; Indoles; Lung Transplantation; Male; Middle Aged; Precision Medicine; Prognosis; Pyridones; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2019 |
Evaluation and management of Idiopathic Pulmonary Fibrosis.
Topics: Biomarkers; Chronic Disease; Cough; Diagnosis, Differential; Disease Progression; Dyspnea; Humans; Idiopathic Pulmonary Fibrosis; Indoles; L-Lactate Dehydrogenase; Mucin-1; Pyridones; Respiratory Function Tests; Tomography, X-Ray Computed; Vital Capacity | 2019 |
Current and future anti-fibrotic therapies for chronic liver disease.
Topics: Angiotensin II; Chronic Disease; Colchicine; Collagen; Extracellular Matrix; Hepatic Stellate Cells; Humans; Interferon-gamma; Ligands; Liver Cirrhosis; PPAR gamma; Pyridones | 2008 |
Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Drug Evaluation; Fibrosis; Humans; Kidney; Kidney Diseases; Pyridones | 2010 |
Progress toward novel treatments for chronic kidney disease.
Topics: Amides; Anticoagulants; Antihypertensive Agents; Bicarbonates; Chronic Disease; Enzyme Inhibitors; Fumarates; Glycosaminoglycans; Humans; Indoles; Iron Chelating Agents; Kidney Diseases; Kidney Failure, Chronic; Maleimides; Pentoxifylline; Phosphodiesterase Inhibitors; Protein Kinase C; Pyridones; Renin; Renin-Angiotensin System | 2010 |
1 trial(s) available for pirfenidone and Chronic Illness
| Article | Year |
|---|---|
Topical Administration of Pirfenidone Increases Healing of Chronic Diabetic Foot Ulcers: A Randomized Crossover Study.
Topics: Administration, Cutaneous; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Foot; Female; Humans; Male; Middle Aged; Pyridones; Treatment Outcome; Wound Healing | 2016 |
13 other study(ies) available for pirfenidone and Chronic Illness
| Article | Year |
|---|---|
Improving outcomes and managing costs in idiopathic pulmonary fibrosis.
Topics: Antineoplastic Agents; Chronic Disease; Comorbidity; Cost of Illness; Health Expenditures; Health Resources; Health Services; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Medication Adherence; Patient Care Management; Patient Education as Topic; Practice Guidelines as Topic; Pyridones; Quality of Life; Registries | 2019 |
Pirfenidone in chronic lung allograft dysfunction: a single cohort study.
Topics: Aged; Chronic Disease; Female; Forced Expiratory Volume; Humans; Lung; Lung Transplantation; Male; Middle Aged; Postoperative Complications; Pyridones; Recovery of Function; Retrospective Studies; Time Factors; Treatment Outcome | 2020 |
The effect of pirfenidone on rat chronic prostatitis/chronic pelvic pain syndrome and its mechanisms.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cell Polarity; Chronic Disease; Chronic Pain; Cytokines; Disease Models, Animal; Inflammation Mediators; Lipid Peroxidation; Macrophages; Male; NF-kappa B; Pelvic Pain; Phosphorylation; Prostatitis; Pyridones; Rats; Syndrome | 2020 |
Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management.
Topics: Acute Disease; Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Antigens; Bronchoalveolar Lavage Fluid; Chronic Disease; Disease Progression; Enzyme Inhibitors; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Indoles; Lung; Lung Transplantation; Pyridones; Tomography, X-Ray Computed | 2017 |
Renoprotective effects of pirfenidone on chronic renal allograft dysfunction by reducing renal interstitial fibrosis in a rat model.
Topics: Allografts; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Fibrosis; Graft Rejection; Kidney Transplantation; Kidney Tubules; Male; Protective Agents; Pyridones; Rats; Rats, Inbred F344; Rats, Inbred Lew; Renal Insufficiency, Chronic | 2019 |
Renoprotective properties of pirfenidone in subtotally nephrectomized rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Differentiation; Cell Line; Chronic Disease; Disease Progression; Enalapril; Epithelial Cells; Fibrosis; Kidney; Kidney Failure, Chronic; Male; Mesoderm; Nephrectomy; Proteinuria; Pyridones; Rats; Rats, Wistar; Transforming Growth Factor beta | 2010 |
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Humans; Idiopathic Pulmonary Fibrosis; Lung; Pyridones; Respiratory Function Tests | 2012 |
Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Gas Analysis; Chronic Disease; Feasibility Studies; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Pulmonary Fibrosis; Pyridones; Radiography, Thoracic; Respiratory Function Tests; Scleroderma, Systemic; Time Factors; Treatment Outcome | 2002 |
Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Chronic Disease; Disease Models, Animal; Graft Rejection; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Postoperative Complications; Pyridones; Trachea; Transplantation, Homologous | 2004 |
Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclosporine; Disease Models, Animal; Female; Graft Rejection; Immunosuppressive Agents; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyridones; Sirolimus; Trachea; Transforming Growth Factor beta | 2005 |
Do we have a pill for renal fibrosis?
Topics: Chronic Disease; Fibrosis; Humans; Kidney; Kidney Diseases; Pyridones; Tablets | 2007 |
Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Clinical Trials as Topic; Fibrinolytic Agents; Graft Rejection; Humans; Lung Transplantation; Pulmonary Fibrosis; Pyridones; Reperfusion Injury | 2007 |
Chronic progressive interstitial fibrosis in renal disease--are there novel pharmacological approaches?
Topics: Animals; Chronic Disease; Extracellular Matrix Proteins; Fibrosis; Humans; Kidney; Pyridones; Renin-Angiotensin System; Tumor Necrosis Factor-alpha | 1999 |